Agents that target telomerase reverse transcriptase (tert) for treating cancer and sensitizing cancer cells to genotoxic therapy
AssigneesNorthwestern University, The University of Chicago
InventorsKarl A. Scheidt, Stephen J. Kron, Yue Liu
Life of this patent
Estimating the term…
Abstract
Disclosed herein are agents that target telomerase reverse transcriptase (TERT) for treating cancer and sensitizing cancer cells to genotoxic therapy. The methods include inhibiting induction of an immunosuppressive factor in a subject in need thereof, the method comprising administering an inhibitor of TERT to the subject.
Claims22
1-22. (canceled)
A method for reducing or preventing resistance or recurrence of a tumor in a subject administered a genotoxic therapy, the method comprising co-administering an inhibitor of telomerase reverse transcriptase (TERT) with the genotoxic therapy to the subject.
34-35. (canceled)
44-82. (canceled)
Dependencies are inferred from the claim text.